Abivax S.A. reported its financial results for the six months ending June 30, 2024, on September 9, 2024, showing a net loss of €81.6 million, a 57% increase from €51.9 million in 2023, due to rising R&D and administrative expenses. Total operating income rose to €6.8 million, driven largely by €4.1 million in subsidies, with plans to continue advancing clinical trials and development of its drug candidate obefazimod.